BSE Live
Dec 30, 16:01Prev. Close
2006.90
Open Price
2009.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 30, 15:57Prev. Close
2009.70
Open Price
2004.60
Bid Price (Qty.)
2029.80 (78)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Glenmark Pharma (in Rs. Cr.) | Mar 05 | Mar 04 | |
| Per Share Ratios | |||
| Basic EPS (Rs.) | 5.35 | 7.09 | |
| Diluted EPS (Rs.) | 5.35 | 7.09 | |
| Cash EPS (Rs.) | 6.61 | 8.93 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 22.48 | 37.99 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 22.48 | 37.99 | |
| Dividend / Share(Rs.) | 0.70 | 1.30 | |
| Revenue from Operations/Share (Rs.) | 41.77 | 59.18 | |
| PBDIT/Share (Rs.) | 10.00 | 12.40 | |
| PBIT/Share (Rs.) | 8.74 | 10.57 | |
| PBT/Share (Rs.) | 7.33 | 8.87 | |
| Net Profit/Share (Rs.) | 5.35 | 7.09 | |
| Profitability Ratios | |||
| PBDIT Margin (%) | 23.94 | 20.96 | |
| PBIT Margin (%) | 20.92 | 17.85 | |
| PBT Margin (%) | 17.54 | 14.98 | |
| Net Profit Margin (%) | 12.81 | 11.98 | |
| Return on Networth / Equity (%) | 23.80 | 18.66 | |
| Return on Capital Employed (%) | 8.66 | 13.35 | |
| Return on Assets (%) | 7.54 | 9.25 | |
| Total Debt/Equity (X) | 1.64 | 0.51 | |
| Asset Turnover Ratio (%) | 58.92 | 77.25 | |
| Liquidity Ratios | |||
| Current Ratio (X) | 5.46 | 1.86 | |
| Quick Ratio (X) | 4.43 | 1.27 | |
| Inventory Turnover Ratio (X) | 4.46 | 4.27 | |
| Dividend Payout Ratio (NP) (%) | 13.08 | 18.33 | |
| Dividend Payout Ratio (CP) (%) | 10.58 | 14.56 | |
| Earnings Retention Ratio (%) | 86.92 | 81.67 | |
| Cash Earnings Retention Ratio (%) | 89.42 | 85.44 | |
| Valuation Ratios | |||
| Enterprise Value (Cr.) | 3,695.52 | 972.03 | |
| EV/Net Operating Revenue (X) | 7.46 | 2.77 | |
| EV/EBITDA (X) | 31.15 | 13.23 | |
| MarketCap/Net Operating Revenue (X) | 6.76 | 2.44 | |
| Retention Ratios (%) | 86.91 | 81.66 | |
| Price/BV (X) | 12.55 | 3.80 | |
| Price/Net Operating Revenue | 6.76 | 2.44 | |
| Earnings Yield | 0.02 | 0.05 |
23.12.2025
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
03.12.2025
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015